Orismilast modified release tablets

DRUG2 trials

Sponsors

UNION therapeutics

Conditions

Atopic DermatitisPsoriasisSkin Diseases

Phase 2

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

CompletedNCT05190419

UNION therapeuticsPsoriasis, Skin Diseases

Start: 2021-12-30End: 2022-12-20Updated: 2024-04-16

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

CompletedNCT05469464

UNION therapeuticsAtopic Dermatitis, Skin Diseases

Start: 2022-07-11End: 2024-02-15Updated: 2025-03-07

Related Papers

Orismilast, a Potent and Selective <scp>PDE4B</scp>/D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis

Experimental Dermatology2025-09-011 citations

Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)

British Journal of Dermatology2025-01-076 citations

Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS).

2023-11-1016 citations